Catheter Precision Announces First Procedures in France as LockeT Expansion Continues
Rhea-AI Summary
Catheter Precision (NYSE:VTAK), a US-based medical device company, has announced the successful completion of its first LockeT procedures in France at CHU Rennes. The procedures were led by Professor Raphael Martins and his team, marking a significant milestone in the company's European expansion.
This development follows the recent CE Mark approval for LockeT, a device designed to improve procedural efficiency and patient outcomes after cardiac ablation procedures. CHU Rennes, which is also a commercial partner for VTAK's VIVO product line, represents the company's growing presence in the European medical device market.
Positive
- First successful LockeT procedures completed in France, expanding European market presence
- Partnership with CHU Rennes extends across multiple product lines (LockeT and VIVO)
- Rapid market entry following CE Mark approval indicates strong market demand
Negative
- None.
News Market Reaction – VTAK
In the Aug 28 session, VTAK gained 5.31%, reflecting a notable positive market reaction. Argus tracked a peak move of +4.6% during that session. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FORT MILL, S.C., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (VTAK - NYSE/American), a US based medical device company and leader in innovative cardiac electrophysiology solutions, is proud to announce the first LockeT procedures in France. This milestone demonstrates significant progress in the adoption and commercialization of its technologies across the continent.
The first procedures with LockeT in France and Europe were successfully completed at CHU Rennes, led by Professor Raphael Martins and his esteemed team. It was recently announced that CHU Rennes is also a commercial partner for the Company’s VIVO product line.
Fatih Ayoglu, Sales Manager for EMEA & APAC at Catheter Precision, said, “This marks a pivotal moment in the clinical rollout of LockeT, which is designed to enhance procedural efficiency and patient outcomes after cardiac ablation procedures. Completing product evaluations so soon after the CE Mark was received is a testament to the need of a product like LockeT in the European Market. We look forward to expanding the commercial footprint and continuing our partnership with Professor Martins and the team at CHU Rennes.”
About LockeT
Catheter Precision’s LockeT is a suture retention device intended to assist in wound closure after percutaneous venous punctures. LockeT is a Class 1 device registered with the FDA and has received CE Mark approval.
About VIVO™
Catheter Precision’s VIVO (View Into Ventricular Onset), is a non-invasive 3D imaging system that enables physicians to identify the origin of ventricular arrhythmias pre-procedure, thereby streamlining workflow and reducing procedure time. VIVO has received marketing clearance from the U.S. FDA and has the CE Mark.
About Catheter Precision
Catheter Precision is an innovative U.S.-based medical device company bringing new solutions to market to improve the treatment of cardiac arrhythmias. It is focused on developing groundbreaking technology for electrophysiology procedures by collaborating with physicians and continuously advancing its products.
Cautionary Note Regarding Forward-Looking Statements
Statements in this press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to substantial risk and uncertainties. Forward-looking statements can be identified by words such as “believe,” “anticipate,” “may,” “might,” “can,” “could,” “continue,” “depends,” “expect,” “expand,” “forecast,” “intend,” “predict,” “plan,” “rely,” “should,” “will,” “may,” “seek,” or the negative of these terms and other similar expressions, although not all forward-looking statements contain these words. These forward-looking statements include, but are not limited to, statements regarding product evaluations at the hospital, and that the purchase order indicates that the hospital and its staff see the value and benefits that LockeT can bring and expectations regarding LockeT evaluations in the coming weeks. The Company’s expectations and beliefs regarding these matters may not materialize. Actual outcomes and results may differ materially from those contemplated by these forward-looking statements as a result of uncertainties, risks and changes in circumstances, including but not limited to risks and uncertainties included under the caption “Risk Factors” in the Company’s Form 10-K filed with the SEC and available at www.sec.gov.
The forward-looking statements included in this communication are made only as of the date hereof. The Company assumes no obligation and does not intend to update these forward-looking statements, except as required by law.
CONTACTS:
Investor Relations
973-691-2000
IR@catheterprecision.com
# # #
